Zealand Pharma achieved notable organizational growth in 2025, with a 41% increase in the number of employees compared to 2024. Despite this rapid expansion, the company improved its high employee ...

Patients with moderate‑to‑severe plaque psoriasis achieve greater relief from itching, skin pain, and scaling with ...

The drugmaker terminated the first-in-human Phase I/II trial after a year, determining that the clinical data did not support further investigation.

By Padmanabhan Ananthan Feb 18 (Reuters) - Cencora will sell its subsidiary MWI Animal Health to privately held Covetrus in a deal valuing the unit at $3.5 billion, the companies said on Wednesday, as ...

Results support the neuroplastogen as a "potential acute, intermittent" therapy, researche ...

While the issue affects only about 2.5 percent of doses sold nationwide, Wisconsin officials say dogs that received that lot will not be recognized as fully vaccinated.

Boehringer Ingelheim is discarding an inhaled gene therapy designed to treat cystic fibrosis (CF) after terminating a phase 1/2 trial. | Boehringer Ingelheim is discarding an inhaled gene therapy ...

OSHKOSH, Wis. (WBAY) - Dog owners are being warned of a nationwide rabies vaccine recall. Boehringer Ingelheim says the vials ...

Both dupilumab and mepolizumab were originally approved for asthma but were subsequently studied in patients with COPD who continue to experience symptoms and moderate-to-severe exacerbations despite ...

The 2025–2030 Dietary Guidelines for Americans, jointly issued by the US Departments of Health and Human Services and Agriculture, introduce a revised dietary pyramid that prioritises animal-based ...

The original Medical Research Council (MRC) dyspnoea scale was developed by the British MRC in the 1950s, and it was first formally published in 1961 in a study on chronic bronchitis.1 It was designed ...